Kunin CM. A guide to use of antibiotics in patients with renal disease. Ann Intern Med 1967; 67: 151–8
PubMed CAS Google Scholar
Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996; 50: 929–36
Keller F, Borner K, Schwarz A, et al. Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit 1987; 9: 148–53
Dettli L. Drug dosage in patients with renal disease. Clin Pharmacol Ther 1974; 16: 274–80
PubMed CAS Google Scholar
Holford NHG. The target concentration approach to clinical drug development. Clin Pharmacokinet 1995; 29: 287–91
Perna A, Gotti E, De Bernardis E, et al. A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity. J Am Soc Nephrol 1996; 7: 786–91
PubMed CAS Google Scholar
Zhi J, Nightingale CH, Quintiliani R. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J Pharmacokinet Biopharm 1988; 16: 355–75
PubMed CAS Google Scholar
Nolting A, Dalla-Costa T, Rand KH, et al. Pharmacokineticpharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res 1996; 13: 91–6
Mouton JW, Vinks AATMM, Punt NC. Pharmacokineticpharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997; 41: 733–8
PubMed CAS Google Scholar
Wagner JG. Kinetics of pharmacological response. I. Proposed relationship between response and drug concentration in the intact animal and man. J Theoret Biol 1968; 20: 173–201
Holford NHG, Sheiner LB. Kinetics of pharmacological response. Pharmacol Ther 1982; 16: 143–66
Hochhaus G, Derendorf H. Dose optimization based on pharmacokinetic-pharmacodynamic modeling. In: Derendorf H, Hochhaus G, editors. Handbook of PK/PD correlation. Boca Raton: CRC Press, 1995: 79–120
Wiedemann B, Jansen A. Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model. J Antimicrob Chemother 1990; 26: 71–9
Firsov AA, Shevchenko AA, Vostrov SN, et al. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother 1998; 42: 659–65
PubMed CAS Google Scholar
Hill AV. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol (Proc Physiol Soc) 1910; 40: iv–vii
Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457–78
PubMed CAS Google Scholar
Krzyzanski W, Jusko WJ. Integrated functions for four basic models of indirect pharmacodynamic response. J Pharm Sci 1998; 87: 67–72
Czock D, Giehl M. Aminoglycoside pharmacokinetics and — dynamics: a nonlinear approach. Int J Clin Pharmacol Ther 1995; 33: 537–9
PubMed CAS Google Scholar
Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–9
Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice-daily gentamicin in patients with serious infections. Lancet 1993; 341: 335–9
Matzke GR, Jameson JJ, Halstenson CE. Gentamicin disposition in young and elderly patients with various degrees of renal function. J Clin Pharmacol 1987; 27: 216–20
PubMed CAS Google Scholar
Halstenson CE, Wong MO, Herman CS, et al. Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease. Antimicrob Agents Chemother 1992; 36: 1832–6
Weiner DL. NONLIN84/PCNONLIN: software for the statistical analysis of nonlinear models. Methods Find Exp Clin Pharmacol 1986; 8: 625–8
PubMed CAS Google Scholar
Gibaldi M, Levy G. Dose-dependent decline of pharmacologic effects of drugs with linear pharmacokinetic characteristics. J Pharm Sci 1972; 61: 567–9
Karlsson MO, Molnar V, Bergh J, et al. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 1998; 63: 11–25
Bouvier d’Yvoire MJY, Maire PH. Dosage regimens of antibacterials. Implications of a pharmacokinetic/pharmacodynamic model. Clin Drug Invest 1996; 11: 229–39
Yano Y, Oguma T, Nagata H, et al. Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci 1998; 87: 1177–83
Mouton JW, Van Ogtrop ML, Andes D, et al. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 1999; 43: 2473–8
PubMed CAS Google Scholar
Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28: 143–60
Bastone EB, Li Shu C, Ioannides-Demos LL, et al. Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing. Antimicrob Agents Chemother 1993; 37: 914–7
Rayner CR, Ioannides-Demos LL, Brien JE, et al. Initial concentration-time profile of gentamicin determines efficacy against Enterobacter cloacae ATCC 13047. Antimicrob Agents Chemother 1998; 42: 1370–4
PubMed CAS Google Scholar
Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717–25
PubMed CAS Google Scholar
Giuliano RA, Verpooten GA, Verbist L, et al. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986; 236: 470–5
PubMed CAS Google Scholar
Takano M, Ohishi Y, Okuda M, et al. Transport of gentamicin and fluid-phase endocytosis markers in the LLC-PK1 kidney epithelial cell line. J Pharmacol Exp Ther 1994; 268: 669–74
PubMed CAS Google Scholar
Wood CA, Norton DR, Kohlhepp SJ, et al. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 1988; 158: 13–22
Bertino JS, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167: 173–9
Bennett WM, Plamp CE, Gilbert DN, et al. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979; 140: 576–80
Giuliano RA, Verpooten GA, De Broe ME. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. Am J Kidney Dis 1986; 5: 297–303
Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45: 22–7
Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39: 650–5
Pattyn VM, Verpooten GA, Giuliano RA, et al. Effect of hyperfiltration, proteinuria and diabetes mellitus on the uptake kinetics of gentamicin in the kidney cortex of rats. J Pharmacol Exp Ther 1988; 244: 694–8
PubMed CAS Google Scholar
Kirkpatrick CMJ, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999; 47: 637–43
Schentag JJ, Jusko WJ, Vance JW, et al. Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm 1977; 5: 559–77
PubMed CAS Google Scholar
Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605–9
